BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 17392715)

  • 1. Technology insight: cytotoxic drug immunoconjugates for cancer therapy.
    Ricart AD; Tolcher AW
    Nat Clin Pract Oncol; 2007 Apr; 4(4):245-55. PubMed ID: 17392715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-cytotoxic agent conjugates for cancer therapy.
    Chen J; Jaracz S; Zhao X; Chen S; Ojima I
    Expert Opin Drug Deliv; 2005 Sep; 2(5):873-90. PubMed ID: 16296784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies.
    Ducry L; Stump B
    Bioconjug Chem; 2010 Jan; 21(1):5-13. PubMed ID: 19769391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoconjugates against solid tumors: mind the gap.
    Ricart AD
    Clin Pharmacol Ther; 2011 Apr; 89(4):513-23. PubMed ID: 21368753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts.
    Ostermann E; Garin-Chesa P; Heider KH; Kalat M; Lamche H; Puri C; Kerjaschki D; Rettig WJ; Adolf GR
    Clin Cancer Res; 2008 Jul; 14(14):4584-92. PubMed ID: 18628473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-conjugated monoclonal antibodies for the treatment of cancer.
    Lambert JM
    Curr Opin Pharmacol; 2005 Oct; 5(5):543-9. PubMed ID: 16087399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukemia.
    Amadori S; Stasi R
    Curr Opin Hematol; 2008 Mar; 15(2):95-100. PubMed ID: 18300754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of monoclonal antibodies in cancer therapy: present and promise.
    Stern M; Herrmann R
    Crit Rev Oncol Hematol; 2005 Apr; 54(1):11-29. PubMed ID: 15780905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted drug delivery using immunoconjugates: principles and applications.
    Pasquetto MV; Vecchia L; Covini D; Digilio R; Scotti C
    J Immunother; 2011; 34(9):611-28. PubMed ID: 21989410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent antibody drug conjugates for cancer therapy.
    Senter PD
    Curr Opin Chem Biol; 2009 Jun; 13(3):235-44. PubMed ID: 19414278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance.
    Hamann PR; Hinman LM; Beyer CF; Greenberger LM; Lin C; Lindh D; Menendez AT; Wallace R; Durr FE; Upeslacis J
    Bioconjug Chem; 2005; 16(2):346-53. PubMed ID: 15769088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arming antibodies: prospects and challenges for immunoconjugates.
    Wu AM; Senter PD
    Nat Biotechnol; 2005 Sep; 23(9):1137-46. PubMed ID: 16151407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Advances in research on monoclonal antibody agents for cancer therapy].
    Zhen Y
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2000 Feb; 22(1):9-13. PubMed ID: 12903485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.
    Shor B; Gerber HP; Sapra P
    Mol Immunol; 2015 Oct; 67(2 Pt A):107-16. PubMed ID: 25304309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of potent monoclonal antibody auristatin conjugates for cancer therapy.
    Doronina SO; Toki BE; Torgov MY; Mendelsohn BA; Cerveny CG; Chace DF; DeBlanc RL; Gearing RP; Bovee TD; Siegall CB; Francisco JA; Wahl AF; Meyer DL; Senter PD
    Nat Biotechnol; 2003 Jul; 21(7):778-84. PubMed ID: 12778055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies.
    Majidi J; Barar J; Baradaran B; Abdolalizadeh J; Omidi Y
    Hum Antibodies; 2009; 18(3):81-100. PubMed ID: 19729803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer antibodies.
    Ross JS; Gray K; Gray GS; Worland PJ; Rolfe M
    Am J Clin Pathol; 2003 Apr; 119(4):472-85. PubMed ID: 12710120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy.
    Brumlik MJ; Daniel BJ; Waehler R; Curiel DT; Giles FJ; Curiel TJ
    Expert Opin Drug Deliv; 2008 Jan; 5(1):87-103. PubMed ID: 18095930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-targeted drugs for the therapy of cancer.
    Pietersz GA; Krauer K
    J Drug Target; 1994; 2(3):183-215. PubMed ID: 7812691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.